Literature DB >> 12767274

Secretion of endogenous kallikreins 2 and 3 by androgen receptor-transfected PC-3 prostate cancer cells.

Alexandra Kollara1, Eleftherios P Diamandis, Theodore J Brown.   

Abstract

Androgen independent PC-3 cells lack androgen receptor (AR) expression and do not produce kallikrein 2 (hK2) or 3 (prostate-specific antigen, PSA). In this paper, we examined the ability of androgens to stimulate PSA and hK2 production in AR transfected PC-3 cells (PC-3(AR)) and compared this to LNCaP cells. PSA and hK2 were measured in the culture medium and cell lysates using an ELISA-based immunofluorometric assay. Only androgens were able to induce PSA and hK2 secretion in PC-3(AR) cells in a dose- and time-dependent manner depending on the level of AR present. The level of androgen-induced PSA and hK2 secretion in PC-3(AR) cells was approximately 1.5 and 0.9% that induced in LNCaP cells, respectively. Insulin-like growth factor-I (IGF-I), which has been shown to activate AR in the absence of ligand, did not activate PSA secretion in the absence of androgen, but further increased the dihydrotestosterone-induced PSA secretion in PC-3(AR) cells. The lack of PSA and hK2 production in parental PC-3 cells is thus a result of their lack of AR expression. PSA and/or hK2 production in PC-3(AR) cells can thus serve as an endogenous reporter system to investigate AR action or to screen putative endocrine disrupters.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12767274     DOI: 10.1016/s0960-0760(03)00069-4

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  5 in total

1.  Transcriptional activity of androgen receptor is modulated by two RNA splicing factors, PSF and p54nrb.

Authors:  Xuesen Dong; Joan Sweet; John R G Challis; Theodore Brown; Stephen J Lye
Journal:  Mol Cell Biol       Date:  2007-04-23       Impact factor: 4.272

2.  Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation.

Authors:  Yuanjie Niu; Shuyuan Yeh; Hiroshi Miyamoto; Gonghui Li; Saleh Altuwaijri; Jianqun Yuan; Ruifa Han; Tengxiang Ma; Hann-Chorng Kuo; Chawnshang Chang
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

3.  A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM).

Authors:  Nessa Banville; Janette K Burgess; Jade Jaffar; Gavin Tjin; Luca Richeldi; Stefania Cerri; Elisa Persiani; Judith L Black; Brian G Oliver
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

4.  Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2.

Authors:  O Vilhelmsson Timmermand; E Larsson; D Ulmert; T A Tran; Se Strand
Journal:  EJNMMI Res       Date:  2016-03-17       Impact factor: 3.138

5.  Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics.

Authors:  Oskar Vilhelmsson Timmermand; Jörgen Elgqvist; Kai A Beattie; Anders Örbom; Erik Larsson; Sophie E Eriksson; Daniel L J Thorek; Bradley J Beattie; Thuy A Tran; David Ulmert; Sven-Erik Strand
Journal:  Theranostics       Date:  2019-04-06       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.